CoreFirst Bank & Trust Has $786,000 Stake in Amgen Inc. (NASDAQ:AMGN)

CoreFirst Bank & Trust lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,523 shares of the medical research company’s stock after acquiring an additional 280 shares during the period. CoreFirst Bank & Trust’s holdings in Amgen were worth $786,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Capital World Investors lifted its holdings in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after purchasing an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new position in Amgen during the 4th quarter valued at about $1,541,991,000. GAMMA Investing LLC increased its position in shares of Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after buying an additional 3,653,205 shares during the period. Capital International Investors lifted its holdings in shares of Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Amgen by 52.7% in the fourth quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company’s stock worth $858,020,000 after buying an additional 1,135,884 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.76% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on AMGN. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective for the company. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a report on Wednesday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Finally, Royal Bank Of Canada decreased their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $307.82.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $298.25 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company has a 50-day moving average price of $282.47 and a 200-day moving average price of $286.99. The company has a market cap of $160.37 billion, a price-to-earnings ratio of 27.21, a price-to-earnings-growth ratio of 2.70 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.96 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.